Published in J Med Chem on January 27, 2005
Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal (2010) 1.40
2,3-dihydro-1H-cyclopenta[b]quinoline derivatives as acetylcholinesterase inhibitors-synthesis, radiolabeling and biodistribution. Int J Mol Sci (2012) 0.95
Acetylcholinesterase inhibitors with photoswitchable inhibition of β-amyloid aggregation. ACS Chem Neurosci (2014) 0.82
Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr Med Chem (2015) 0.81
Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease. Sci Rep (2016) 0.80
Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors. Acta Pharmacol Sin (2009) 0.79
AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease. Curr Neuropharmacol (2016) 0.77
Advances in recent patent and clinical trial drug development for Alzheimer's disease. Pharm Pat Anal (2014) 0.76
Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? Open Neurol J (2009) 0.75
Small molecular floribundiquinone B derived from medicinal plants inhibits acetylcholinesterase activity. Oncotarget (2017) 0.75
Pharmacodynamic study of FS-0311: a novel highly potent, selective acetylcholinesterase inhibitor. Cell Mol Neurobiol (2007) 0.75
Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem (2008) 1.81
Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis (2002) 1.22
beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol (2003) 1.16
Sulforaphane as a promising molecule for fighting cancer. Mutat Res (2006) 1.12
Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem (2007) 1.10
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J Med Chem (2005) 1.05
Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res (2011) 1.05
Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J Med Chem (2007) 1.05
Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity. J Med Chem (2008) 1.04
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes. J Med Chem (2002) 1.03
Modulation of phase II enzymes by sulforaphane: implications for its cardioprotective potential. J Agric Food Chem (2009) 1.03
Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxid Med Cell Longev (2013) 1.03
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem (2008) 1.03
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem (2009) 1.01
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica (2012) 1.00
Micronuclei frequencies in hospital workers occupationally exposed to low levels of ionizing radiation: influence of smoking status and other factors. Mutagenesis (2002) 0.98
Strategies for the inhibition of protein aggregation in human diseases. Chembiochem (2010) 0.98
Natural isothiocyanates: genotoxic potential versus chemoprevention. Mutat Res (2011) 0.95
Micronuclei in humans induced by exposure to low level of ionizing radiation: influence of polymorphisms in DNA repair genes. Mutat Res (2005) 0.94
A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl (2007) 0.93
Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. Mutat Res (2006) 0.93
Micronucleus frequency in human peripheral blood lymphocytes as a biomarker for the early detection of colorectal cancer risk. Mutagenesis (2014) 0.93
Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem (2005) 0.92
Sulforaphane protects cortical neurons against 5-S-cysteinyl-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes. Mol Nutr Food Res (2010) 0.92
Parallel synthesis and cytotoxicity evaluation of a polyamine-quinone conjugates library. J Med Chem (2008) 0.92
Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem (2006) 0.92
Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem (2008) 0.91
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res (2012) 0.91
Protective effects of cyanidin-3-O-beta-glucopyranoside against UVA-induced oxidative stress in human keratinocytes. Photochem Photobiol (2005) 0.91
Sulforaphane as a promising molecule for fighting cancer. Cancer Treat Res (2014) 0.91
Plasma antioxidant enzymes and clastogenic factors as possible biomarkers of colorectal cancer risk. Mutat Res (2011) 0.91
Protein flexibility in virtual screening: the BACE-1 case study. J Chem Inf Model (2012) 0.90
Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Anal Bioanal Chem (2011) 0.89
Oxidative stress in Alzheimer's disease: are we connecting the dots? J Med Chem (2013) 0.89
Histone post-translational modifications by HPLC-ESI-MS after HT29 cell treatment with histone deacetylase inhibitors. Proteomics (2009) 0.89
Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem (2012) 0.88
Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett (2007) 0.88
Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chem Biol Interact (2010) 0.88
Spectrum of chromosomal aberrations in peripheral lymphocytes of hospital workers occupationally exposed to low doses of ionizing radiation. Mutat Res (2004) 0.88
Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol (2009) 0.87
Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem (2004) 0.87
Exposure to low environmental levels of benzene: evaluation of micronucleus frequencies and S-phenylmercapturic acid excretion in relation to polymorphisms in genes encoding metabolic enzymes. Mutat Res (2010) 0.87
Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy. Pharmacogenomics (2013) 0.86
Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. Eur J Med Chem (2011) 0.86
Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics (2009) 0.86
Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Neurotoxicology (2013) 0.86
Neuroprotective effects of cyanidin 3-O-glucopyranoside on amyloid beta (25-35) oligomer-induced toxicity. Neurosci Lett (2010) 0.86
Kinetic characterization of amyloid-beta 1-42 aggregation with a multimethodological approach. Anal Biochem (2011) 0.86
Inherited susceptibility to bleomycin-induced micronuclei: correlating polymorphisms in GSTT1, GSTM1 and DNA repair genes with mutagen sensitivity. Mutat Res (2007) 0.86
Characterization of reversible and pseudo-irreversible acetylcholinesterase inhibitors by means of an immobilized enzyme reactor. J Chromatogr A (2006) 0.85
Effects of environmental benzene: micronucleus frequencies and haematological values in traffic police working in an urban area. Mutat Res (2005) 0.85
Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on human transformed and non-transformed cells. Biochem Pharmacol (2004) 0.84
Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J Med Chem (2007) 0.84
Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells. Ann N Y Acad Sci (2009) 0.84
Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem Res (2014) 0.83
Inhibition by beta-caryophyllene of ethyl methanesulfonate-induced clastogenicity in cultured human lymphocytes. Mutat Res (2010) 0.83
Induction of apoptosis in two human leukemia cell lines as well as differentiation in human promyelocytic cells by cyanidin-3-O-beta-glucopyranoside. Biochem Pharmacol (2004) 0.83
Neuroprotective effects of anthocyanins and their in vivo metabolites in SH-SY5Y cells. Neurosci Lett (2007) 0.83
Micronuclei frequency induced by bleomycin in human peripheral lymphocytes: correlating BLHX polymorphism with mutagen sensitivity. Mutat Res (2007) 0.83
Sulforaphane as an inducer of glutathione prevents oxidative stress-induced cell death in a dopaminergic-like neuroblastoma cell line. J Neurochem (2009) 0.83
Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal Bioanal Chem (2007) 0.82
Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J Med Chem (2012) 0.82
Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. J Med Chem (2006) 0.82